Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Effects of Diet on Brain Processing
The Effect of a Ketogenic Diet on HIV-Associated Neurocognitive Impairment
Status: Enrolling
Updated:  12/31/1969
UAB 1917 Clinic
mi
from
Birmingham, AL
Effects of Diet on Brain Processing
The Effect of a Ketogenic Diet on HIV-Associated Neurocognitive Impairment
Status: Enrolling
Updated: 12/31/1969
UAB 1917 Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated:  12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Multimedia WORTH With Black Drug-Involved Women on Probation
Multimedia HIV/STI Prevention for Black Drug-Involved Women on Probation
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Multimedia WORTH With Black Drug-Involved Women on Probation
Multimedia HIV/STI Prevention for Black Drug-Involved Women on Probation
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
601 University of California, Los Angeles CARE Center CRS
mi
from
Los Angeles, CA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
601 University of California, Los Angeles CARE Center CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
31788 Alabama CRS
mi
from
Birmingham, AL
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
31788 Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
7804 Weill Cornell Chelsea CRS
mi
from
New York, NY
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
7804 Weill Cornell Chelsea CRS
mi
from
New York, NY
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)
mi
from
New York, NY
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)
mi
from
New York, NY
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
2951 The Miriam Hospital (TMH) ACTG CRS
mi
from
Providence, RI
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
2951 The Miriam Hospital (TMH) ACTG CRS
mi
from
Providence, RI
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
31473 Houston AIDS Research Team (HART) CRS
mi
from
Houston, TX
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
31473 Houston AIDS Research Team (HART) CRS
mi
from
Houston, TX
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
University of Southern California CRS (1201)
mi
from
Los Angeles, CA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
University of Southern California CRS (1201)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Ucsd, Avrc Crs (701)
mi
from
San Diego, CA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
University of Miami AIDS CRS (901)
mi
from
Miami, FL
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
201 Johns Hopkins University CRS
mi
from
Baltimore, MD
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
201 Johns Hopkins University CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
101 Massachusetts General Hospital (MGH) CRS
mi
from
Boston, MA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
101 Massachusetts General Hospital (MGH) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
107 Brigham and Women's Hosp. ACTG CRS
mi
from
Boston, MA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
107 Brigham and Women's Hosp. ACTG CRS
mi
from
Boston, MA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
3203 Greensboro CRS
mi
from
Greensboro, NC
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
3203 Greensboro CRS
mi
from
Greensboro, NC
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
31443 Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
31443 Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Click here to add this to my saved trials
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated:  12/31/1969
31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
PREPARE (A5361s) Substudy of REPRIEVE (A5332)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Status: Enrolling
Updated: 12/31/1969
31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Clinical research Center of Alabama
mi
from
Birmingham, AL
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Clinical research Center of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Research Solutions of Arizona
mi
from
Litchfield Park, AZ
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Research Solutions of Arizona
mi
from
Litchfield Park, AZ
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Long Island Jewish Medical Center
mi
from
Great Neck, NY
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Long Island Jewish Medical Center
mi
from
Great Neck, NY
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Levine Children's Hospital
mi
from
Charlotte, NC
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Levine Children's Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Duke University School of Medicine
mi
from
Durham, NC
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
The Ottawa Hospital
mi
from
Ottawa,
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
The Ottawa Hospital
mi
from
Ottawa,
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
University of Southern Florida
mi
from
Saint Petersburg, FL
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
University of Southern Florida
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Georgia Pollens Clinical Research Centers, Inc
mi
from
Albany, GA
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Georgia Pollens Clinical Research Centers, Inc
mi
from
Albany, GA
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Icahn Medical Institute
mi
from
New York, NY
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Icahn Medical Institute
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Research Rochester General Hospital
mi
from
Rochester, NY
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Research Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials